APRE - Aprea Therapeutics, Inc.

QQQ $ 451.63 $ -0.22 (-0.05 %)

DIA $ 399.76 $ 0.74 (0.19 %)

SPY $ 529.24 $ 0.76 (0.14 %)

TLT $ 91.40 $ -0.62 (-0.67 %)

GLD $ 223.63 $ 3.63 (1.65 %)

Previous Close

$ 5.27

Open

$ 5.85

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 5.35 - $ 5.85

52 Week Range

$ 2.78 - $ 8.85

Volume

7,978

Average Volume

Market Cap

22.13M

Beta (5Y Monthly)

$ 0.80

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	03-26-2024	12-31-2023	10-K
3	11-09-2023	09-30-2023	10-Q
4	08-10-2023	06-30-2023	10-Q
5	05-15-2023	03-31-2023	10-Q
6	03-30-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-12-2022	06-30-2022	10-Q
9	05-16-2022	03-31-2022	10-Q
10	03-15-2022	12-31-2021	10-K
11	11-08-2021	09-30-2021	10-Q
12	08-12-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	03-16-2021	12-31-2020	10-K
15	11-06-2020	09-30-2020	10-Q
16	08-11-2020	06-30-2020	10-Q
17	05-15-2020	03-31-2020	10-Q
18	03-27-2020	12-31-2019	10-K
19	11-14-2019	09-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on Apre...
05/14/2024 15:15:35

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

Aprea Therapeutics Q1 EPS $(0.67) Beats $(...
05/14/2024 12:47:24

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(...

Aprea Therapeutics Announces Presentations...
04/10/2024 16:02:28

Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and...

12-health-care-stocks-moving-in-thursdays-pre-market-session

12 Health Care Stocks Moving In Thursday's...
04/04/2024 12:09:11

Wedbush Maintains Outperform on Aprea Ther...
03/27/2024 11:54:52

Wedbush analyst Robert Driscoll maintains Aprea Therapeutics (NASDAQ:APRE) with a Outperform and raises the price target fro...

HC Wainwright & Co. Maintains Buy on Aprea...
03/26/2024 15:12:14

HC Wainwright & Co. analyst Joseph Pantginis maintains Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pri...

Aprea Therapeutics: Q4 Earnings Insights
03/26/2024 13:10:10

why-is-precision-oncology-focused-aprea-therapeutics-stock-trading-higher-on-monday

Why Is Precision Oncology-Focused Aprea Th...
03/11/2024 13:39:22

FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising WEE1 kinase inhibitor. Phase 1 trial initiation...

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
03/11/2024 13:05:55

Market-Moving News for March 11th
03/11/2024 12:40:56

DUO: 151% | Fangdd Network shares are trading higher after the company announced its 2024 strategic layout with plans to enter ...

Aprea Therapeutics shares are trading high...
03/11/2024 12:38:35

Aprea Therapeutics Announces Private Place...
03/11/2024 12:32:56

Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 mi...

Aprea Therapeutics Announces FDA Clearance...
03/11/2024 12:30:35

Company plans to initiate Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumo...

Aprea Therapeutics Announces Submission Of...
02/06/2024 13:03:03

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company ...

Aprea Therapeutics Entered Into An At-mark...
01/26/2024 12:22:00

-8-K

Aprea Therapeutics Provided A Corporate Up...
01/04/2024 21:12:52

Update on Phase 1/2a Ongoing Trial of ATR Program, ATRN-119Enrollment of patients continues in the dose escalation portion of t...

Aprea Therapeutics Q3 EPS $(0.86) Beats $(...
11/09/2023 22:27:36

Aprea Therapeutics (NASDAQ:APRE) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(...

HC Wainwright & Co. Reiterates Buy on Apre...
11/01/2023 10:59:04

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:APRE) with a Buy and maintains $20 pr...

A Look Into Healthcare Sector Value Stocks
10/30/2023 14:43:46

Aprea Unveils Initial Clinical Data On ATR...
10/16/2023 12:45:45

Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical stage biopharmaceutical company ...